Index RUT
P/E -
EPS (ttm) -0.91
Insider Own 14.36%
Shs Outstand 35.17M
Perf Week -2.28%
Market Cap 864.69M
Forward P/E 35.77
EPS next Y 0.68
Insider Trans 3.65%
Shs Float 30.30M
Perf Month 14.53%
Income -31.33M
PEG -
EPS next Q -0.18
Inst Own 58.17%
Short Float 18.37%
Perf Quarter 144.40%
Sales 138.68M
P/S 6.24
EPS this Y 28.33%
Inst Trans -4.54%
Short Ratio 12.26
Perf Half Y 153.00%
Book/sh 1.70
P/B 14.39
EPS next Y 227.13%
ROA -12.23%
Short Interest 5.57M
Perf Year 14.80%
Cash/sh 2.15
P/C 11.38
EPS next 5Y 15.00%
ROE -76.44%
52W Range 7.60 - 25.58
Perf YTD 118.21%
Dividend Est. -
P/FCF 135.74
EPS past 5Y -
ROI -12.49%
52W High -4.46%
Beta 0.75
Dividend TTM -
Quick Ratio 2.73
Sales past 5Y 27.34%
Gross Margin 69.77%
52W Low 221.58%
ATR (14) 0.98
Dividend Ex-Date -
Current Ratio 2.99
EPS Y/Y TTM -40.50%
Oper. Margin -5.28%
RSI (14) 65.79
Volatility 4.12% 4.07%
Employees 315
Debt/Eq 3.19
Sales Y/Y TTM 49.79%
Profit Margin -22.59%
Recom 1.00
Target Price 29.15
Option/Short Yes / Yes
LT Debt/Eq 3.18
EPS Q/Q -74.37%
Payout -
Rel Volume 0.51
Prev Close 24.23
Sales Surprise -4.77%
EPS Surprise -74.71%
Sales Q/Q 32.50%
Earnings Aug 07 AMC
Avg Volume 454.06K
Price 24.44
SMA20 5.01%
SMA50 21.25%
SMA200 81.59%
Trades
Volume 231,051
Change 0.87%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-11-24 Initiated
Craig Hallum
Buy
$24
Sep-08-22 Resumed
B. Riley Securities
Buy
$17
Oct-14-21 Resumed
B. Riley Securities
Buy
$16
Sep-24-21 Initiated
Aegis Capital
Buy
$15
Jul-02-21 Initiated
Ladenburg Thalmann
Buy
$14.25
Jul-25-24 07:00AM
Jul-12-24 07:00AM
Jul-09-24 07:00AM
Jul-02-24 11:52AM
Jun-20-24 07:00AM
06:30AM
Loading…
Jun-07-24 06:30AM
Jun-06-24 08:00AM
Jun-05-24 07:00AM
May-15-24 07:00AM
May-13-24 08:55PM
04:25PM
04:01PM
07:00AM
Apr-25-24 07:00AM
Apr-02-24 08:16AM
09:55AM
Loading…
Mar-21-24 09:55AM
Mar-19-24 09:52PM
06:51PM
05:45PM
Mar-13-24 06:35AM
Mar-05-24 07:00AM
Mar-04-24 08:28PM
Feb-21-24 06:47AM
Feb-15-24 04:01PM
Jan-29-24 07:00AM
Jan-11-24 07:00AM
Jan-03-24 07:15AM
07:00AM
Dec-24-23 01:08PM
Nov-29-23 07:00AM
07:00AM
Loading…
Nov-20-23 07:00AM
Nov-14-23 12:56PM
Nov-13-23 05:07PM
04:01PM
Oct-30-23 08:00AM
Oct-24-23 07:00AM
Sep-29-23 08:00AM
Sep-26-23 08:00AM
Sep-21-23 01:03PM
Aug-11-23 01:05PM
Aug-10-23 09:54AM
(Thomson Reuters StreetEvents) -15.45%
Aug-09-23 04:14PM
(Associated Press Finance)
04:01PM
Jul-31-23 07:00AM
Jul-28-23 02:56PM
Jul-26-23 03:42PM
(American City Business Journals)
09:00AM
Jul-20-23 10:29AM
Jul-19-23 12:17PM
07:00AM
Jul-18-23 05:00PM
04:05PM
04:04PM
04:01PM
Jul-05-23 06:15PM
Jun-29-23 06:15PM
Jun-23-23 06:15PM
Jun-16-23 06:00PM
May-17-23 08:00AM
May-16-23 11:57AM
May-15-23 11:21AM
May-12-23 01:48PM
06:26AM
(Thomson Reuters StreetEvents)
May-11-23 05:15PM
04:29PM
04:01PM
May-08-23 12:07PM
May-04-23 08:00AM
04:59AM
May-03-23 06:44AM
May-02-23 04:42PM
09:40AM
07:00AM
May-01-23 08:50AM
Apr-28-23 06:00PM
05:00AM
Apr-27-23 08:05AM
08:00AM
Apr-24-23 08:43AM
07:09AM
Apr-20-23 08:31AM
Apr-19-23 06:15PM
08:31AM
Apr-18-23 06:24AM
Apr-14-23 08:50AM
Apr-13-23 06:15PM
Apr-12-23 09:40AM
Apr-09-23 04:04PM
(The Wall Street Journal)
Apr-05-23 09:34AM
Apr-04-23 05:37AM
Apr-03-23 06:53AM
Mar-29-23 08:50AM
Mar-28-23 02:59PM
07:00AM
Mar-27-23 08:51AM
Mar-24-23 05:42AM
(Thomson Reuters StreetEvents) +6.78%
Mar-23-23 04:06PM
Mar-13-23 07:00AM
Mar-06-23 08:00AM
Mar-02-23 08:00AM
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Opaleye Management Inc. 10% Owner Apr 25 '24 Buy 9.97 20,000 199,400 3,815,000 Apr 25 05:19 PM Opaleye Management Inc. 10% Owner Apr 24 '24 Buy 10.15 8,285 84,093 3,795,000 Apr 24 04:40 PM Opaleye Management Inc. 10% Owner Apr 23 '24 Buy 10.29 11,715 120,547 3,786,715 Apr 24 04:40 PM Opaleye Management Inc. 10% Owner Apr 19 '24 Buy 10.56 29,400 310,390 3,775,000 Apr 19 06:24 PM Opaleye Management Inc. 10% Owner Mar 28 '24 Buy 12.82 50,000 641,000 3,745,600 Mar 28 06:07 PM BAUM MARK L CHIEF EXECUTIVE OFFICER Mar 22 '24 Buy 11.59 9,000 104,310 2,137,525 Mar 25 07:00 AM Opaleye Management Inc. 10% Owner Mar 20 '24 Buy 9.65 50,600 488,290 3,695,600 Mar 22 11:52 AM SAHAREK JOHN P. CEO of ImprimisRx Mar 01 '24 Option Exercise 8.75 5,000 43,750 254,803 Mar 06 06:06 AM BAUM MARK L CHIEF EXECUTIVE OFFICER Feb 20 '24 Option Exercise 10.67 150,000 1,600,500 2,188,361 Feb 21 07:29 PM BOLL ANDREW R. CHIEF FINANCIAL OFFICER Feb 20 '24 Option Exercise 10.67 45,000 480,150 586,569 Feb 21 07:29 PM SAHAREK JOHN P. CEO of ImprimisRx Feb 20 '24 Option Exercise 10.67 30,000 320,100 262,419 Feb 21 07:30 PM BAUM MARK L CHIEF EXECUTIVE OFFICER Feb 07 '24 Option Exercise 7.71 15,400 118,734 2,038,361 Feb 08 07:30 AM BOLL ANDREW R. CHIEF FINANCIAL OFFICER Feb 07 '24 Option Exercise 7.71 7,400 57,054 541,569 Feb 08 07:30 AM BAUM MARK L Chief Executive Officer Nov 16 '23 Buy 8.11 7,500 60,825 2,022,961 Nov 16 04:45 PM Opaleye Management Inc. 10% Owner Nov 15 '23 Buy 8.03 25,000 200,735 3,645,000 Nov 16 04:05 PM Opaleye Management Inc. 10% Owner Sep 20 '23 Buy 14.49 5,983 86,710 3,620,000 Sep 20 06:39 PM Opaleye Management Inc. 10% Owner Sep 19 '23 Buy 14.65 14,017 205,366 3,614,017 Sep 20 06:39 PM Makary Martin A. Director Aug 14 '23 Buy 16.92 20,000 338,400 45,000 Aug 15 07:30 AM BAUM MARK L Chief Executive Officer Aug 14 '23 Buy 17.05 5,800 98,890 2,015,461 Aug 15 07:30 AM
Index -
P/E 0.01
EPS (ttm) 106.40
Insider Own 2.20%
Shs Outstand 2.68M
Perf Week 5.46%
Market Cap 1.70M
Forward P/E -
EPS next Y -0.19
Insider Trans 0.00%
Shs Float 2.62M
Perf Month -56.29%
Income -
PEG -
EPS next Q -1.05
Inst Own 11.31%
Short Float 6.34%
Perf Quarter -64.59%
Sales 12.14M
P/S 0.14
EPS this Y -28.20%
Inst Trans -
Short Ratio 1.15
Perf Half Y -84.47%
Book/sh -0.66
P/B -
EPS next Y 93.30%
ROA -
Short Interest 0.17M
Perf Year -88.50%
Cash/sh -
P/C -
EPS next 5Y -
ROE -
52W Range 0.60 - 14.75
Perf YTD -81.90%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -
52W High -95.70%
Beta 1.36
Dividend TTM -
Quick Ratio -
Sales past 5Y -
Gross Margin -
52W Low 5.63%
ATR (14) 0.16
Dividend Ex-Date -
Current Ratio -
EPS Y/Y TTM 102.58%
Oper. Margin -
RSI (14) 36.93
Volatility 11.95% 24.86%
Employees 17
Debt/Eq -
Sales Y/Y TTM -100.00%
Profit Margin -
Recom 3.00
Target Price 6.00
Option/Short No / Yes
LT Debt/Eq -
EPS Q/Q -
Payout -
Rel Volume 0.01
Prev Close 0.66
Sales Surprise -
EPS Surprise -11.76%
Sales Q/Q -
Earnings May 14 AMC
Avg Volume 144.86K
Price 0.63
SMA20 -22.70%
SMA50 -44.07%
SMA200 -80.17%
Trades
Volume 1,578
Change -3.25%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-16-21 Upgrade
BTIG Research
Neutral → Buy
$14
Feb-10-21 Initiated
Maxim Group
Buy
$24
Dec-23-19 Reiterated
H.C. Wainwright
Buy
$15 → $18
Mar-01-19 Reiterated
Needham
Buy
$7
Jun-13-17 Reiterated
Stifel
Buy
$14 → $6
Dec-21-16 Initiated
Jefferies
Buy
$10
Feb-01-16 Resumed
Oppenheimer
Outperform
Jul-29-15 Initiated
ROTH Capital
Buy
$18
Mar-02-15 Reiterated
Stifel
Buy
$16 → $20
Mar-02-15 Reiterated
Oppenheimer
Outperform
$22 → $26
Feb-24-15 Initiated
Stifel
Buy
$16
Feb-24-15 Initiated
Oppenheimer
Outperform
$22
Show Previous Ratings
Jul-03-24 04:32AM
(Clinical Trials Arena) -15.01%
Jul-02-24 09:13AM
(Pharmaceutical Technology) -9.91%
Jul-01-24 09:00AM
Jun-11-24 08:00AM
May-15-24 06:53AM
(Thomson Reuters StreetEvents) -17.77%
03:10AM
Loading…
03:10AM
May-14-24 08:56PM
04:10PM
(Associated Press Finance)
04:01PM
May-07-24 04:01PM
Apr-10-24 06:30AM
Apr-08-24 09:10AM
Apr-03-24 08:00AM
Mar-07-24 10:03AM
Mar-05-24 04:29PM
(Associated Press Finance)
+5.07%
04:02PM
Loading…
04:02PM
Feb-28-24 04:02PM
Dec-20-23 08:00AM
Nov-21-23 07:55AM
07:32AM
Nov-20-23 08:00AM
Nov-13-23 09:29AM
Nov-12-23 08:47AM
Nov-10-23 07:45AM
Nov-09-23 04:58PM
(Associated Press Finance)
04:02PM
Oct-31-23 04:02PM
(GlobeNewswire) +11.35%
-5.74%
Sep-18-23 08:00AM
Sep-05-23 04:02PM
Aug-25-23 07:20AM
08:43AM
Loading…
Aug-15-23 08:43AM
(Thomson Reuters StreetEvents) -6.95%
Aug-14-23 07:00PM
(Associated Press Finance) -9.66%
04:02PM
Aug-02-23 04:05PM
Jul-11-23 08:00AM
Jun-20-23 08:00AM
Jun-16-23 08:00AM
Jun-15-23 08:00AM
Jun-02-23 08:00AM
May-30-23 08:00AM
May-11-23 11:24AM
(Thomson Reuters StreetEvents) -6.14%
May-10-23 04:38PM
04:02PM
May-03-23 04:02PM
Apr-25-23 07:41AM
Apr-06-23 08:30AM
Mar-14-23 12:00PM
Mar-10-23 02:26AM
Mar-09-23 05:49AM
(Thomson Reuters StreetEvents)
Mar-08-23 04:02PM
Feb-28-23 04:02PM
Jan-20-23 06:55AM
Jan-10-23 08:30AM
Dec-27-22 08:00AM
Dec-14-22 11:29AM
08:00AM
Nov-21-22 08:00AM
Nov-14-22 04:02PM
(GlobeNewswire) +9.03%
-9.47%
Oct-31-22 08:00AM
Oct-06-22 08:30AM
08:00AM
Sep-14-22 08:00AM
Sep-07-22 08:00AM
Sep-06-22 08:00AM
Aug-29-22 08:00PM
11:45AM
08:00AM
Aug-10-22 04:02PM
08:00AM
Aug-08-22 08:00AM
Jul-27-22 08:05AM
Jul-26-22 08:05AM
Jun-02-22 08:05AM
May-16-22 08:05AM
May-11-22 04:02PM
May-04-22 08:05AM
Apr-19-22 08:05AM
Apr-08-22 05:02PM
Mar-23-22 08:05AM
Mar-15-22 04:02PM
Mar-11-22 08:05AM
Mar-10-22 08:05AM
Mar-04-22 08:05AM
Feb-02-22 08:05AM
Jan-05-22 08:05AM
Dec-27-21 08:00AM
Nov-29-21 08:05AM
Nov-11-21 08:05AM
Nov-03-21 04:02PM
Oct-27-21 08:05AM
Oct-13-21 08:00AM
Oct-11-21 01:27PM
08:00AM
Sep-13-21 08:05AM
Sep-07-21 08:05AM
07:29AM
Sep-02-21 08:05AM
Aug-11-21 04:02PM
Aug-09-21 08:05AM
Aug-03-21 08:05AM
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
Index -
P/E -
EPS (ttm) -3.74
Insider Own 7.36%
Shs Outstand 20.59M
Perf Week 5.38%
Market Cap 48.39M
Forward P/E -
EPS next Y -3.65
Insider Trans -24.15%
Shs Float 19.07M
Perf Month 20.20%
Income -42.47M
PEG -
EPS next Q -0.74
Inst Own 42.27%
Short Float 9.44%
Perf Quarter -22.95%
Sales 0.00M
P/S -
EPS this Y -0.45%
Inst Trans -2.32%
Short Ratio 6.58
Perf Half Y 0.00%
Book/sh 5.11
P/B 0.46
EPS next Y -1.84%
ROA -48.67%
Short Interest 1.80M
Perf Year -13.28%
Cash/sh 2.68
P/C 0.88
EPS next 5Y -
ROE -55.45%
52W Range 1.04 - 5.24
Perf YTD 25.33%
Dividend Est. -
P/FCF -
EPS past 5Y 39.98%
ROI -67.81%
52W High -55.15%
Beta 1.82
Dividend TTM -
Quick Ratio 10.53
Sales past 5Y 0.00%
Gross Margin -
52W Low 125.96%
ATR (14) 0.21
Dividend Ex-Date -
Current Ratio 10.53
EPS Y/Y TTM 34.41%
Oper. Margin 0.00%
RSI (14) 50.29
Volatility 6.89% 10.34%
Employees 27
Debt/Eq 0.09
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 27.80
Option/Short Yes / Yes
LT Debt/Eq 0.07
EPS Q/Q -21.41%
Payout -
Rel Volume 0.36
Prev Close 2.29
Sales Surprise -
EPS Surprise -5.43%
Sales Q/Q -
Earnings May 02 BMO
Avg Volume 273.39K
Price 2.35
SMA20 5.24%
SMA50 -7.75%
SMA200 -7.10%
Trades
Volume 98,679
Change 2.62%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-10-23 Resumed
Guggenheim
Buy
$22
Jun-04-21 Initiated
H.C. Wainwright
Buy
$40
Feb-17-21 Initiated
Oppenheimer
Outperform
$43
Oct-19-20 Initiated
Cowen
Outperform
$50
Jul-29-20 Initiated
Guggenheim
Buy
$50
Jun-24-24 05:06PM
May-21-24 08:00AM
May-02-24 12:54PM
08:00AM
Apr-12-24 09:55AM
08:04AM
Loading…
Apr-05-24 08:04AM
08:02AM
08:00AM
Mar-13-24 08:00AM
Feb-28-24 08:00AM
Jan-31-24 07:30AM
Nov-30-23 08:30AM
Nov-03-23 09:43AM
08:00AM
Oct-23-23 08:00AM
08:30AM
Loading…
Sep-20-23 08:30AM
Sep-05-23 07:30AM
Aug-03-23 08:00AM
May-15-23 08:00AM
May-04-23 08:00AM
May-02-23 08:00AM
Apr-28-23 08:00AM
Mar-08-23 08:00AM
Mar-01-23 08:00AM
Feb-02-23 08:00AM
Jan-30-23 08:00AM
Dec-01-22 08:00AM
Nov-03-22 08:00AM
Oct-24-22 08:35AM
Sep-06-22 08:00AM
08:00AM
Loading…
Aug-09-22 08:00AM
Jun-21-22 08:00AM
May-26-22 05:11PM
May-17-22 08:00AM
07:32AM
May-12-22 08:00AM
May-05-22 08:00AM
Apr-11-22 09:55AM
Mar-24-22 08:00AM
Mar-23-22 10:00AM
Mar-09-22 07:30AM
Mar-08-22 05:50AM
Mar-02-22 08:00AM
Feb-01-22 08:00AM
Jan-10-22 08:00AM
Jan-04-22 08:00AM
Dec-08-21 11:15AM
Nov-04-21 08:00AM
Oct-25-21 04:45PM
Oct-12-21 07:00AM
Sep-17-21 04:05PM
Sep-13-21 07:00AM
Sep-09-21 10:31AM
Sep-07-21 08:00AM
Aug-05-21 08:00AM
Jul-07-21 08:00AM
Jun-22-21 07:30AM
Jun-10-21 08:00AM
May-13-21 08:00AM
May-06-21 07:30AM
Apr-23-21 07:00AM
Apr-19-21 04:09PM
08:00AM
Apr-12-21 11:12AM
Mar-30-21 07:01AM
Mar-11-21 07:30AM
Mar-10-21 08:00AM
Feb-04-21 08:00AM
Feb-02-21 08:00AM
08:00AM
Dec-16-20 11:07PM
Dec-07-20 04:30PM
Dec-03-20 07:00AM
Nov-24-20 07:00AM
Nov-12-20 07:15AM
Nov-11-20 07:00AM
Nov-04-20 07:00AM
Sep-28-20 03:12PM
Sep-22-20 08:13AM
Sep-21-20 04:01PM
Sep-08-20 07:00AM
Sep-02-20 05:49PM
Aug-03-20 07:00AM
Jul-28-20 07:00AM
Jul-24-20 07:00AM
Jul-03-20 06:34PM
Jul-02-20 07:59PM
04:05PM
Jun-02-20 04:05PM
May-26-20 08:30AM
May-13-20 08:00AM
May-11-20 08:38AM
May-05-20 04:05PM
Apr-02-20 07:00AM
Feb-11-20 08:00AM
Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Opaleye Management Inc. 10% Owner Jul 16 '24 Sale 2.44 11,396 27,828 56,500 Jul 18 04:05 PM Opaleye Management Inc. 10% Owner Jul 11 '24 Sale 2.40 47,993 115,346 60,000 Jul 11 07:56 PM Opaleye Management Inc. 10% Owner Jul 10 '24 Sale 2.31 18,061 41,685 75,000 Jul 11 07:56 PM Opaleye Management Inc. 10% Owner Jul 09 '24 Sale 2.21 8,497 18,811 80,000 Jul 11 07:56 PM Opaleye Management Inc. 10% Owner Jul 01 '24 Sale 2.12 8,288 17,598 87,500 Jul 03 02:00 PM Opaleye Management Inc. 10% Owner Jun 28 '24 Sale 2.07 17,994 37,334 85,000 Jun 28 06:45 PM Opaleye Management Inc. 10% Owner Jun 27 '24 Sale 2.26 46,574 105,169 90,000 Jun 28 06:45 PM Opaleye Management Inc. 10% Owner Jun 25 '24 Sale 2.26 12,725 28,734 102,471 Jun 27 04:05 PM Opaleye Management Inc. 10% Owner May 31 '24 Sale 2.90 5,824 16,895 108,696 May 31 04:05 PM Opaleye Management Inc. 10% Owner May 30 '24 Sale 2.94 9,230 27,113 114,520 May 31 04:05 PM Opaleye Management Inc. 10% Owner May 22 '24 Sale 3.02 9,800 29,596 123,750 May 23 07:01 PM Opaleye Management Inc. 10% Owner May 21 '24 Sale 3.06 33,000 100,838 124,250 May 23 07:01 PM Opaleye Management Inc. 10% Owner May 17 '24 Sale 3.25 70,885 230,326 126,050 May 17 07:48 PM Opaleye Management Inc. 10% Owner May 10 '24 Sale 3.11 151,700 472,424 2,380,294 May 10 06:57 PM Opaleye Management Inc. 10% Owner May 09 '24 Sale 3.09 30,600 94,526 2,531,994 May 10 06:57 PM
Index -
P/E -
EPS (ttm) -1.67
Insider Own 28.39%
Shs Outstand 24.49M
Perf Week -0.65%
Market Cap 113.44M
Forward P/E -
EPS next Y -1.15
Insider Trans -1.44%
Shs Float 17.66M
Perf Month -11.37%
Income -40.30M
PEG -
EPS next Q -0.46
Inst Own 47.07%
Short Float 10.96%
Perf Quarter 4.78%
Sales 63.15M
P/S 1.80
EPS this Y 25.36%
Inst Trans 17.14%
Short Ratio 8.55
Perf Half Y -38.67%
Book/sh 0.58
P/B 7.88
EPS next Y 24.25%
ROA -61.70%
Short Interest 1.94M
Perf Year -52.82%
Cash/sh 1.51
P/C 3.05
EPS next 5Y -
ROE -459.89%
52W Range 4.03 - 10.22
Perf YTD -30.51%
Dividend Est. -
P/FCF -
EPS past 5Y 5.17%
ROI -73.20%
52W High -54.99%
Beta 1.02
Dividend TTM -
Quick Ratio 3.23
Sales past 5Y 49.61%
Gross Margin 68.97%
52W Low 14.14%
ATR (14) 0.28
Dividend Ex-Date -
Current Ratio 4.13
EPS Y/Y TTM 37.33%
Oper. Margin -71.62%
RSI (14) 45.24
Volatility 4.43% 6.78%
Employees 227
Debt/Eq 2.87
Sales Y/Y TTM 40.03%
Profit Margin -63.82%
Recom 1.00
Target Price 14.20
Option/Short Yes / Yes
LT Debt/Eq 2.83
EPS Q/Q 63.26%
Payout -
Rel Volume 0.46
Prev Close 4.50
Sales Surprise 1.74%
EPS Surprise 52.95%
Sales Q/Q 39.42%
Earnings May 09 AMC
Avg Volume 226.23K
Price 4.60
SMA20 -0.03%
SMA50 -12.26%
SMA200 -19.60%
Trades
Volume 104,942
Change 2.22%
Date
Action
Analyst
Rating Change
Price Target Change
May-31-22 Initiated
Lake Street
Buy
$17
Dec-03-19 Initiated
Piper Jaffray
Overweight
Dec-03-19 Initiated
JMP Securities
Mkt Outperform
Dec-03-19 Initiated
Jefferies
Buy
Dec-03-19 Initiated
Canaccord Genuity
Buy
Jul-25-24 04:05PM
Jul-22-24 04:05PM
Jun-04-24 04:05PM
May-20-24 04:03PM
May-13-24 11:01AM
04:05PM
Loading…
May-10-24 04:05PM
03:51PM
10:15AM
May-09-24 04:05PM
May-02-24 04:10PM
Apr-25-24 07:00AM
Apr-15-24 07:00AM
Apr-08-24 07:00AM
Mar-22-24 09:46AM
07:07AM
(Thomson Reuters StreetEvents)
08:53PM
Loading…
Mar-21-24 08:53PM
05:32PM
05:30PM
04:05PM
07:00AM
Mar-20-24 07:00AM
07:00AM
Feb-29-24 07:00AM
Feb-23-24 04:05PM
Jan-19-24 04:05PM
Dec-15-23 04:05PM
Dec-05-23 07:00AM
Nov-16-23 07:00AM
Nov-12-23 12:20PM
Nov-10-23 04:05PM
04:05PM
Loading…
Nov-09-23 04:05PM
Oct-26-23 07:00AM
Sep-18-23 04:05PM
Aug-16-23 07:00AM
Aug-11-23 10:03AM
Aug-10-23 09:18AM
(Thomson Reuters StreetEvents)
Aug-09-23 06:05PM
04:03PM
Aug-04-23 04:02PM
Jul-26-23 07:00AM
Jul-06-23 10:09AM
Jun-18-23 07:51PM
Jun-15-23 07:00AM
May-25-23 07:00AM
May-21-23 10:30AM
May-19-23 07:00AM
May-12-23 07:44AM
(Thomson Reuters StreetEvents)
May-11-23 05:25PM
04:02PM
May-09-23 07:00AM
May-08-23 04:30PM
May-02-23 07:00AM
Apr-30-23 08:26AM
Apr-28-23 06:47PM
06:47PM
Apr-27-23 07:00AM
Apr-18-23 11:00PM
04:01PM
Apr-03-23 06:14AM
Mar-29-23 07:00AM
Mar-24-23 07:15AM
Mar-23-23 07:00AM
Mar-22-23 06:01AM
(Thomson Reuters StreetEvents) -5.91%
Mar-21-23 05:15PM
04:02PM
Mar-16-23 07:00AM
Feb-28-23 07:00AM
Feb-24-23 04:02PM
Feb-21-23 07:00AM
Feb-14-23 07:00AM
Jan-20-23 04:05PM
Jan-09-23 07:00AM
Dec-23-22 05:46AM
Dec-21-22 07:00AM
Dec-09-22 04:02PM
Nov-21-22 07:00AM
Nov-12-22 07:42AM
Nov-09-22 05:25PM
04:01PM
Nov-03-22 07:00AM
Oct-28-22 04:05PM
Oct-27-22 07:00AM
Oct-26-22 07:00AM
Oct-24-22 10:24AM
Sep-01-22 07:00AM
Aug-23-22 04:01PM
Aug-19-22 10:52AM
(American City Business Journals)
Aug-18-22 04:01PM
Aug-16-22 12:01PM
(American City Business Journals) -11.15%
Aug-15-22 10:20PM
04:01PM
Aug-10-22 10:30PM
05:35PM
04:01PM
Aug-05-22 07:00AM
Aug-04-22 07:00AM
Jul-29-22 04:01PM
Jul-27-22 07:00AM
Jul-20-22 07:00AM
Jul-08-22 06:45AM
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
ORBIMED ADVISORS LLC 10% Owner Jul 02 '24 Sale 4.54 36,600 166,164 2,407,242 Jul 02 04:54 PM ORBIMED ADVISORS LLC 10% Owner Jul 01 '24 Sale 4.68 13,700 64,116 2,443,842 Jul 02 04:54 PM ORBIMED ADVISORS LLC 10% Owner Jun 28 '24 Sale 4.74 378,000 1,791,720 2,457,542 Jul 02 04:54 PM Firestone Gregory A. Chief Business Officer Dec 05 '23 Buy 5.65 2,600 14,688 35,511 Dec 07 04:02 PM KOBLISH ANTONY Chief Executive Officer Nov 14 '23 Buy 4.54 11,000 49,976 303,634 Nov 14 08:01 PM Cuca Roberto COO and CFO Nov 14 '23 Buy 4.49 10,000 44,938 62,371 Nov 14 08:02 PM
Index -
P/E 105.92
EPS (ttm) 0.03
Insider Own 5.34%
Shs Outstand 25.69M
Perf Week 2.29%
Market Cap 91.97M
Forward P/E 13.26
EPS next Y 0.27
Insider Trans 0.00%
Shs Float 24.32M
Perf Month 6.55%
Income 0.91M
PEG -
EPS next Q -0.07
Inst Own 28.10%
Short Float 0.25%
Perf Quarter 14.74%
Sales 34.30M
P/S 2.68
EPS this Y -50.00%
Inst Trans 6.71%
Short Ratio 1.20
Perf Half Y -19.37%
Book/sh 0.60
P/B 5.94
EPS next Y 550.00%
ROA 3.34%
Short Interest 0.06M
Perf Year 26.50%
Cash/sh 0.65
P/C 5.52
EPS next 5Y -
ROE 6.83%
52W Range 2.42 - 5.81
Perf YTD -18.26%
Dividend Est. -
P/FCF 15.64
EPS past 5Y 63.71%
ROI 5.89%
52W High -38.38%
Beta 1.28
Dividend TTM -
Quick Ratio 1.43
Sales past 5Y 11165.96%
Gross Margin 66.24%
52W Low 47.93%
ATR (14) 0.16
Dividend Ex-Date -
Current Ratio 1.59
EPS Y/Y TTM 114.58%
Oper. Margin 1.58%
RSI (14) 57.15
Volatility 3.51% 4.54%
Employees 30
Debt/Eq 0.33
Sales Y/Y TTM 40.71%
Profit Margin 2.66%
Recom 1.00
Target Price 8.00
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q 69.77%
Payout -
Rel Volume 0.36
Prev Close 3.57
Sales Surprise 3.45%
EPS Surprise 57.14%
Sales Q/Q 50.19%
Earnings May 09 AMC
Avg Volume 50.64K
Price 3.58
SMA20 4.46%
SMA50 2.29%
SMA200 -8.36%
Trades
Volume 18,313
Change 0.28%
Date
Action
Analyst
Rating Change
Price Target Change
May-06-24 Initiated
Craig Hallum
Buy
$8
Oct-14-21 Resumed
B. Riley Securities
Buy
$10
Jan-04-21 Reiterated
H.C. Wainwright
Buy
$20 → $15
Sep-20-19 Initiated
B. Riley FBR
Buy
$13.50
Jun-10-19 Initiated
H.C. Wainwright
Buy
$15
Jul-17-24 04:15PM
Jul-15-24 04:05PM
May-10-24 10:11AM
(Thomson Reuters StreetEvents)
May-09-24 04:01PM
May-01-24 04:05PM
11:21AM
Loading…
Apr-30-24 11:21AM
07:00AM
Apr-29-24 04:30PM
Mar-22-24 02:20AM
02:00AM
Mar-15-24 03:10PM
09:34AM
(Thomson Reuters StreetEvents)
Mar-14-24 08:55PM
05:35PM
05:15PM
04:01PM
Loading…
04:01PM
Feb-29-24 04:01PM
Feb-26-24 08:19AM
Feb-21-24 06:50AM
Feb-02-24 06:50AM
Jan-16-24 07:52AM
(Entrepreneur: Stocks) -6.41%
Nov-11-23 11:09AM
Nov-09-23 04:01PM
Oct-30-23 06:50AM
Oct-23-23 05:16AM
Oct-18-23 08:00AM
Oct-04-23 06:50AM
Sep-22-23 12:04PM
Sep-20-23 09:40AM
Sep-12-23 08:50AM
11:36AM
Loading…
Aug-25-23 11:36AM
Aug-23-23 06:50AM
Aug-16-23 09:15AM
Aug-13-23 07:52AM
Aug-11-23 12:44PM
(Thomson Reuters StreetEvents) +38.08%
Aug-10-23 05:40PM
04:01PM
Aug-08-23 10:50AM
Aug-01-23 04:05PM
Jul-17-23 04:05PM
Jul-15-23 08:40AM
Jun-28-23 06:50AM
May-16-23 11:35AM
May-11-23 05:35PM
04:01PM
May-10-23 06:50AM
May-03-23 04:05PM
Apr-19-23 11:22AM
Mar-22-23 07:17AM
Mar-18-23 02:03AM
Mar-16-23 05:25PM
04:01PM
Mar-15-23 06:50AM
Mar-07-23 04:05PM
Feb-08-23 12:00PM
Feb-05-23 07:30AM
Jan-31-23 08:00AM
Jan-25-23 10:00AM
07:21AM
Jan-24-23 12:26PM
Jan-23-23 11:01AM
10:00AM
07:36AM
Jan-12-23 10:34AM
Jan-11-23 07:27AM
06:50AM
Nov-23-22 12:37PM
Nov-22-22 12:45PM
Nov-16-22 10:33AM
05:34AM
Nov-10-22 05:45PM
04:30PM
(Thomson Reuters StreetEvents)
04:05PM
Nov-02-22 04:05PM
Oct-18-22 04:05PM
06:50AM
Sep-27-22 09:05AM
Sep-13-22 09:00AM
Aug-30-22 04:05PM
Aug-11-22 05:35PM
04:01PM
Aug-08-22 10:00AM
Aug-04-22 10:00AM
Aug-02-22 08:00AM
Jul-18-22 08:09AM
07:05AM
Jun-24-22 09:45AM
07:30AM
Jun-13-22 12:28PM
May-13-22 09:08AM
May-12-22 05:15PM
04:02PM
May-10-22 05:45PM
May-05-22 07:25PM
03:00PM
May-03-22 04:02PM
09:15AM
Apr-12-22 10:03AM
Apr-11-22 04:01PM
07:30AM
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite